Who Paid My Doc
Dawn Eichenfield
Pediatric Dermatology San Diego, CA Medical Doctor
NPI 1295198091 CMS profile 4219371
3030 Childrens Way, San Diego, CA 92123
General payments
$252,065
Research payments
$571
Ownership & investment interest
$0
Research they led as principal investigator
$67,984
Through program year 2025, Dawn Eichenfield of San Diego, CA is reported in the CMS Open Payments database as having received $252,065 across 195 general payments and $571 in research payments paid to them. Separately, studies naming them as principal investigator received $67,984 in research payments, paid to institutions rather than to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.
General payments for this record sit in the 96th percentile of Pediatric Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
8 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $72,306 | 75 | |
| 2025 | Research | $571 | 1 | |
| 2024 | General | $107,159 | 64 | |
| 2023 | General | $45,853 | 28 | |
| 2022 | General | $26,306 | 18 | |
| 2021 | General | $66 | 4 | |
| 2020 | General | $103 | 1 | |
| 2019 | General | $272 | 5 |
Beside peers
- Dawn Eichenfield
- Pediatric Dermatology median
- Middle half of Pediatric Dermatology
- National median
In program year 2025, general payments to Dawn Eichenfield were reported at $72,306. Among 172 Pediatric Dermatology profiles paid that year, the median was $302 and the middle half received between $110 and $2,128.
Show as a table
| Year | Dawn Eichenfield | Pediatric Dermatology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $272 | $280 | $89–$1,853 | $163 |
| 2020 | $103 | $263 | $71–$2,376 | $114 |
| 2021 | $66 | $227 | $69–$1,800 | $132 |
| 2022 | $26,306 | $289 | $69–$1,516 | $149 |
| 2023 | $45,853 | $537 | $114–$3,255 | $160 |
| 2024 | $107,159 | $437 | $114–$2,693 | $164 |
| 2025 | $72,306 | $302 | $110–$2,128 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
196 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Pediatric Dermatology in California
Lawrence Eichenfield
Pediatric Dermatology · San Diego, CA
Joyce Teng
Pediatric Dermatology · Palo Alto, CA
Brandie Metz
Pediatric Dermatology · Irvine, CA
Shireen Guide
Pediatric Dermatology · Palo Alto, CA
Ilka Netravali
Pediatric Dermatology · Palo Alto, CA
Maria Buethe
Pediatric Dermatology · Orange, CA
Related records
Pediatric Dermatology in California
Practitioners in the same specialty and state, ranked by reported value.
All Pediatric Dermatology
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.